LOG IN 
Not a member of My prIME? Join now for instant access.
Event Overview
Share
Send to colleagueMeeting Overview
Stay current on hot topics in acute lymphoblastic leukemia (ALL) with this satellite symposium preceding the 2018 Annual Hematology Meeting. Through a combination of presentations on clinical trial data and current best practices with case scenarios, participants in this event will gain expert insight into critical factors underpinning current recommendations and learn about the cutting edge of ALL management in adolescents and adults. Attendees will have the opportunity to interact with expert faculty throughout the symposium. Join us in San Diego!
Please note that, due to congress restrictions, spots are limited and seats will be given on a first-come, first-served basis. Please arrive by 7.15 AM to guarantee your spot.
Friday Satellite Symposium on How I Treat Acute Lymphoblastic Leukemia: Insight From the Experts, preceding the 60th ASH Annual Meeting and Exposition
Date and Location
Friday, November 30, 2018
7.00 AM – 7.30 AM – Breakfast and Registration
7.30 AM – 10.25 AM – Educational Session
Grand Ballrooms 1-4
Marriott Marquis San Diego Marina
333 W Harbor Dr
San Diego, California 92101
Date/Time
Friday, November 30, 2018
Location
San Diego, California, United States
CME
2.75 AMA PRA Category 1 Credits™
| 7.00 AM | Registration and breakfast |
| 7.30 AM | Welcome and introduction Stephen E. Sallan, MD |
| 7.35 AM | Hematology Guru quiz Stephen E. Sallan, MD |
| 7.45 AM | How I treat AYAs with newly diagnosed ALL Stephen E. Sallan, MD |
| 8.05 AM | Interactive audience Q & A Stephen E. Sallan, MD |
| 8.10 AM | How I treat newly diagnosed ALL in adults David I. Marks, MBBS, PhD, FRACP, FRCPath |
| 8.30 AM | Interactive audience Q & A David I. Marks, MBBS, PhD, FRACP, FRCPath |
| 8.35 AM | How I treat patients with minimal residual disease after induction therapy Dan Douer, MD |
| 8.50 AM | Interactive audience Q & A Dan Douer, MD |
| 8.55 AM | Break |
| 9.10 AM | How I treat relapsed/refractory ALL Dan Douer, MD |
| 9.30 AM | Interactive audience Q & A Dan Douer, MD |
| 9.35 AM | What’s around the corner: Novel treatment approaches for ALL Marlise Luskin, MD, MSCE |
| 9.55 AM | Faculty panel discussion and audience Q & A |
| 10.10 AM | Hematology Guru post-test and prIME Points™ Stephen E. Sallan, MD |
| 10.25 AM | Adjourn |
-
Stephen E. Sallan, MDDana-Farber Cancer Institute
Boston, Massachusetts, United States -
Dan Douer, MDUSC Norris Comprehensive Cancer Center
Los Angeles, California, United States -
Marlise Luskin, MD, MSCEDana-Farber Cancer Institute
Boston, Massachusetts, United States -
David I. Marks, MBBS, PhD, FRACP, FRCPathUniversity Hospitals Bristol NHS Foundation Trust
Bristol, United Kingdom
Chair
Faculty
This educational activity is designed to address the needs of hematologists, oncologists, and other healthcare professionals who manage adolescents/young adults (AYAs) and adults with acute lymphoblastic leukemia (ALL).
After successful completion of this educational activity, participants should be able to:
- Employ optimal induction strategies for the initial treatment of AYAs and adults with ALL
- Analyze the role of minimal residual disease assessment in both the prognosis and treatment planning for AYAs and adults with ALL
- Select optimal strategies for relapsed/refractory ALL in the AYA and adult population
- Describe the role of new and emerging therapies used to treat ALL in AYAs and adults
This educational activity is supported by a grant from Servier.
Continuing Education
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Provider
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Sunshine Act/EFPIA
prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.
Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact Emily Simpson prior to the live event at 678.686.7762.
There is no fee for this activity.
Disclosures
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.